About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and ...

NEW YORK, Jan. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of AstraZeneca PLC (NASDAQ: AZN). Shareholders who purchased shares of AZN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/astrazeneca-plc-loss-submission-form-2/?id=120892&from=3  CLASS PERIOD: February 23, ...

Johnson & Johnson on Tuesday said its lung cancer regimen keeps people alive for at least a year longer than AstraZeneca's Tagrisso, the go-to drug for a certain type of lung cancer.J&J in a statement said its drugs – Rybrevant and Lazcluze – showed a statistically significant and clinically meaningful improvement to survival relative to Tagrisso in a pivotal trial. The company expects the benefit to be at least a year and possibly longer, J&J executives said in an interview. The company plans to present th ...

NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...

NEW YORK, Jan. 6, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm.So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired AstraZeneca PLC (NASDAQ: AZN) securities between February 23, 2022 and December 17, 2024. AstraZeneca describes itself as "a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascul ...

LOS ANGELES, Jan. 6, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between February 23, 2022 and December 17, 2024, inclusive (the "Class Period" ...

AstraZeneca (AZN) stock has declined 14% in the past three months. A lot of this price decline is due to ongoing investigations at its China subsidiary. However, the overall drug and biotech sector has also done poorly in the past three months after Trump announced the appointment of Robert F. Kennedy Jr., a vaccine skeptic, as the head of Health and Human Services, the agency that oversees the FDA.This, coupled with disappointing third-quarter sales and profits, guidance cuts and pipeline setbacks took a t ...

Pharmaceutical Industry Overview - Novo Nordisk and AstraZeneca are among the largest companies in the pharmaceutical industry, both delivering strong financial results in 2024 despite stock price declines [1] - AstraZeneca's shares are down 2% over the trailing-12-month period, while Novo Nordisk's shares are down 14% [1] Novo Nordisk Analysis - Novo Nordisk has a 33.9% share of the diabetes care market as of August 2024, up from 33.3% a year prior [3] - The company holds a 55.6% share of the GLP-1 drug space, compared to 54.4% in August 2023 [3] - Novo Nordisk's GLP-1 drugs Wegovy and Ozempic have driven rapid financial growth [3] - The weight loss market is projected to grow rapidly, with Novo Nordisk having an attractive pipeline in this field [4] - CagriSema, a weight loss drug candidate, showed 22.7% average weight loss in a 68-week study, outperforming Wegovy and Eli Lilly's Zepbound [5] - Novo Nordisk has promising candidates in rare diseases and neurological conditions like Alzheimer's and Parkinson's [6] AstraZeneca Analysis - AstraZeneca has a diversified pipeline spanning oncology, rare diseases, cardiovascular, renal, metabolism, respiratory, immunology, and vaccine therapies [8] - The company has 199 programs in its pipeline, including several promising candidates in the weight loss area [10] - AstraZeneca faces challenges in China due to an insurance fraud investigation and the arrest of its China president, Leon Wang [10][11] - Despite higher quarterly revenue, AstraZeneca's earnings per share are lower [12] Comparative Analysis - Novo Nordisk's revenue growth is expected to outpace AstraZeneca's in the short to mid-term due to its strong GLP-1 medicines and AstraZeneca's potential sales decline in China [14] - Novo Nordisk's recent issues are less damaging to its prospects compared to AstraZeneca's challenges [14]

NEW YORK, Jan. 3, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/astrazeneca-plc-lawsuit- ...